Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Post-Mkt 08-31 17:27:14 EDT

263.04

+15.13

+6.10%

盘后263.04

+0.000.00%

17:07 EDT

High268.98	Low247.65	Vol1.03M
Open247.65	D1 Closing247.91	Amplitude8.60%
Mkt Cap17.41B	Tradable Cap17.24B	Total Shares66.19M
T/O269.94M	T/O Rate1.57%	Tradable Shares65.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":263.04,"timestamp":1788206400000,"preClose":247.91,"halted":0,"volume":1025923,"hourTrading":{"tag":"盘后","latestPrice":263.04,"preClose":263.04,"latestTime":"17:07 EDT","volume":62193,"amount":16359249.207719998,"timestamp":1788210449554,"change":0,"changeRate":0,"amplitude":0.011671},"delay":0,"changeRate":0.06103021257714503,"floatShares":65539518,"shares":66189926,"eps":12.96,"marketStatus":"Post-Mkt","change":15.13,"latestTime":"08-31 17:27:14 EDT","open":247.65,"high":268.98,"low":247.65,"amount":269943988.82514995,"amplitude":0.086039,"askPrice":268.17,"askSize":7,"bidPrice":263.2,"bidSize":10,"shortable":3,"etf":0,"ttmEps":12.96,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":247.91,"preHourTrading":{"tag":"盘前","latestPrice":249.36,"preClose":247.91,"latestTime":"09:20 EDT","volume":543,"amount":134692.48578,"timestamp":1788182446542,"change":1.45,"changeRate":0.005849,"amplitude":0.028962},"postHourTrading":{"tag":"盘后","latestPrice":263.04,"preClose":263.04,"latestTime":"17:07 EDT","volume":62193,"amount":16359249.207719998,"timestamp":1788210449554,"change":0,"changeRate":0,"amplitude":0.011671},"volumeRatio":3.650465,"impliedVol":0.3755,"impliedVolPercentile":0.0956},"requestUrl":"/m/hq/s/ASND/wiki","defaultTab":"wiki","newsList":[{"id":"2663812002","title":"H.C. Wainwright trims Ascendis target, says litigation overhang removed","url":"https://stock-news.laohu8.com/highlight/detail?id=2663812002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663812002?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:15","pubTimestamp":1788189314,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Ascendis Pharma (ASND) to $344 from $345 and keeps a Buy rating on the shares. The Yuviwel royal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-trims-ascendis-target-says-litigation-overhang-removed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-trims-ascendis-target-says-litigation-overhang-removed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4585","LU0889565916.HKD","MEDI","LU0109394709.USD","ASND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004993","title":"Ascendis Pharma a/S : H.c. Wainwright Cuts Target Price to $344 from $345","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004993?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:14","pubTimestamp":1788189270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nAZN4THCX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0109394709.USD","ASND","BK4585","MEDI","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004961","title":"European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004961","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004961?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:12","pubTimestamp":1788189152,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week slightly lower late Monday morning, declining 0.12% to 1,952.52 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma  and 3D printer company Materialise , which rose 6.6% and 2.8%, respectively. They were followed by petroleum refiner Equinor  and oil and gas company Eni , which were up 2.7% and 2.6%, respectively.The decliners from continental Europe were led by internet browser company Opera  and biotech firm Evaxion , which fell 1.9% and 1.7% respectively. They were followed by telecommunications company Nokia  and accommodations booking site trivago , which were down 1.3% and 1.2% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group  and software firm Endava , which advanced 14% and 1.9% respectively. They were followed by oil and gas companies BP  and Shell , which increased 1.3% and 0.9","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WTIU","LU0648005311.SGD","BP","DBC","DRLL","IEO","LU0098860793.USD","SHEH","VDE","LFGY","ERX","EVAX","FTXN","LU0084288595.USD","EPV","IXC","USE","DBE","ASND","PRNT","SHEL","BDRX","DAVA.AU","PXE","MTLS","OPRA","DRIP","DAVA","PXJ","E","GUSH","LU0109394709.USD","LU0278409577.USD","NOK","AFG","LU1829250122.USD","MEDI","TRVG","DIG","XES","SLN","AKTX","LU2236285917.USD","IEUR","MREO","EQNR","NCNA","BPH","LNOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111456454","title":"Movement Alert｜Ascendis Pharma A/S Rises 5.92% in Regular Trading, Global Patent Settlement Reached with BioMarin Over Yuviwel","url":"https://stock-news.laohu8.com/highlight/detail?id=1111456454","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111456454?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:49","pubTimestamp":1788184144,"startTime":"0","endTime":"0","summary":"On August 31, Ascendis Pharma A/S rose 5.92% in regular trading, trading at $262.27/share, with turnover of $34.16 million. The surge was driven by the announcement that Ascendis Pharma and BioMarin...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ascendis Surges on BioMarin Patent Settlement for Yuviwel","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005698","title":"Ascendis Pharma price target lowered to $330 from $333 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005698","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663005698?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:40","pubTimestamp":1788180039,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on Ascendis Pharma (ASND) to $330 from $333 and keeps a Buy rating on the shares after the company settle...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-lowered-to-330-from-333-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-lowered-to-330-from-333-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0889565916.HKD","LU0109394709.USD","ASND","LU0320765992.SGD","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663778980","title":"Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2663778980","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663778980?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:02","pubTimestamp":1788174164,"startTime":"0","endTime":"0","summary":"Ascendis enters global settlement, license deal with BioMarin for YUVIWEL royaltiesAscendis Pharma entered a binding term sheet with BioMarin for a global settlement and license covering YUVIWEL (nave","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL77w2Rq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE0002270589.USD","IE00BN0W2W23.USD","LU2095319765.USD","MEDI","SG9999014005.SGD","IE00B19Z3581.USD","LU0109394709.USD","BK4139","IE00B64PRP62.GBP","BCDF","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","BMRN","LU0320765992.SGD","BK4585","LU0889565916.HKD","IE00B19Z3B42.SGD","BK4566","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","ASND","IE00B7SZLL34.SGD","BK4112","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663072751","title":"Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663072751?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:00","pubTimestamp":1788174001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA3YGTF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4139","LU0320765992.SGD","ASND","MEDI","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663072327","title":"Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663072327?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:42","pubTimestamp":1788172920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","LU0109394709.USD","BK4139","MEDI","LU0889565916.HKD","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663294076","title":"BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2663294076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663294076?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:15","pubTimestamp":1788167708,"startTime":"0","endTime":"0","summary":"BioMarin (BMRN) announced that it has entered into binding terms with Ascendis Pharma (ASND), resolving the patent and ancillary disputes pending g...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomarin-to-receive-20-royalty-on-net-sales-of-yuviwel-from-ascendis-pharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomarin-to-receive-20-royalty-on-net-sales-of-yuviwel-from-ascendis-pharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0320765992.SGD","IE0002270589.USD","LU0109394709.USD","BK4585","BMRN","LU0889565916.HKD","IE00B19Z3581.USD","USRD","IE00B19Z3B42.SGD","MEDI","BK4566","IE00B7SZLL34.SGD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075865","title":"Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663075865?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:36","pubTimestamp":1788165406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S0MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","LU0889565916.HKD","LU0109394709.USD","IE0002270589.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU0320765992.SGD","MEDI","BMRN","IE00B19Z3B42.SGD","ASND","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076078","title":"BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076078","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076078?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:53","pubTimestamp":1788162812,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical  said Monday it entered into a binding agreement to resolve all global patent disputes with Ascendis Pharma  concerning the drug Yuviwel used to treat linear growth failure.Ascendis will pay royalties of 20% on US net sales and 18% on sales in the European Union, Brazil, and South Korea through May 2030, the company said.The license covers all present and future uses of the treatment, including achondroplasia, BioMarin said.The deal terminates pending legal proceedings in the US, Germany, Denmark, Brazil, and South Korea, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BMRN","IE00B7SZLL34.SGD","LU0889565916.HKD","IE00B19Z3581.USD","LU0109394709.USD","ASND","IE0002270589.USD","IE00B19Z3B42.SGD","BK4566","LU0320765992.SGD","MEDI","BK4585","BK7095","BMRN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663022409","title":"Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2663022409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663022409?lang=en_us&edition=fundamental","pubTime":"2026-08-31 14:00","pubTimestamp":1788156001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA7NTQQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","IE00B19Z3581.USD","BMRN","BK4139","IE00B19Z3B42.SGD","MEDI","LU0889565916.HKD","ASND","BK4566","IE0002270589.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701191","title":"HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662701191?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:26","pubTimestamp":1787829987,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has an average rating of buy and mean price target of $310.61, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776703","title":"Ascendis Pharma initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662776703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:16","pubTimestamp":1787825760,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $345 price target The firm believes the shares at current levels...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0320765992.SGD","ASND","MEDI","BK4139","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662547817","title":"Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662547817","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662547817?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:17","pubTimestamp":1787689076,"startTime":"0","endTime":"0","summary":"Aug 25 (Reuters) - Ascendis Pharma A/S::*ASCENDIS ANNOUNCES ORAL PRESENTATION OF WEEK 104 DATA FROM ITS PIVOTAL TRIAL OF TRANSCON® CNP (NAVEPEGRITIDE) AT ISDS 2026((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 25-AUG-202620:01:00.097 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nRSD7Kjp40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","BK4585","BK4139","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754987","title":"Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754987?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUAWL1HN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0889565916.HKD","ASND","BK4585","BK4139","MEDI","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662209662","title":"Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2662209662","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662209662?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:19","pubTimestamp":1787602784,"startTime":"0","endTime":"0","summary":"Ascendis Pharma earnings event and why it matters for shareholders\nAscendis Pharma (NasdaqGS:ASND) recently reported second quarter 2026 results, with sales of €339.29 million and net income of €206.97 million, following a net loss in the same period a year earlier.\nSee our latest analysis for Ascendis Pharma.\nFollowing the strong second quarter earnings shift into profitability, Ascendis Pharma's 7 day share price return of 2.38% and 90 day share price return of 5.69% suggest momentum has...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/ascendis-pharma-asnd-on-profitability-the-valuation-narrativ","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/ascendis-pharma-asnd-on-profitability-the-valuation-narrativ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MEDI","BK4585","LU0109394709.USD","LU0889565916.HKD","BK4139","PCOM","ASND","BK4122","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660781413","title":"Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660781413","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660781413?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:03","pubTimestamp":1787101400,"startTime":"0","endTime":"0","summary":"Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common sharesAscendis Pharma director Jean Jacques Bienaime bought 2,000 ordinary shares in open-market purchases.Purchases were exec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLKYczN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LU0109394709.USD","MEDI","ASND","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464066","title":"Eyconis Announces Initiation of First-in-Human Clinical Trial of Eyc-0305 in Treatment-NaÏVe Wet Age-Related Macular Degeneration Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464066?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:00","pubTimestamp":1787054400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUA17RGMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0889565916.HKD","MEDI","LU0320765992.SGD","BK4139","LU0109394709.USD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659177688","title":"Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2659177688","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659177688?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:45","pubTimestamp":1786887914,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S ( NASDAQ:ASND ) just released its latest second-quarter results and things are looking bullish. It...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/ascendis-pharma-as-just-recorded-a-104-eps-beat-heres-what-a","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/ascendis-pharma-as-just-recorded-a-104-eps-beat-heres-what-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":-0.0212},{"period":"1month","weight":-0.0164},{"period":"3month","weight":0.1062},{"period":"6month","weight":0.0617},{"period":"1year","weight":0.2785},{"period":"ytd","weight":0.1626}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.031281},{"month":2,"riseRate":0.583333,"avgChangeRate":0.050705},{"month":3,"riseRate":0.416667,"avgChangeRate":0.030446},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.031037},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.005122},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035016},{"month":7,"riseRate":0.583333,"avgChangeRate":-0.006819},{"month":8,"riseRate":0.75,"avgChangeRate":0.07923},{"month":9,"riseRate":0.636364,"avgChangeRate":0.039794},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.00981},{"month":11,"riseRate":0.818182,"avgChangeRate":0.047363},{"month":12,"riseRate":0.545455,"avgChangeRate":0.041981}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}